RecruitingPhase 1Phase 2NCT07412704

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Sponsor

Bristol-Myers Squibb

Enrollment

84 participants

Start Date

Sep 15, 2026

Study Type

INTERVENTIONAL

Conditions

Arthritis, Rheumatoid

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BMS-986528 for people with arthritis, rheumatoid. The study is currently recruiting participants at 39 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986528

Specified dose on specified days

Locations(39)

Local Institution - 0068

La Jolla, California, United States

Local Institution - 0070

Loma Linda, California, United States

Local Institution - 0069

Palo Alto, California, United States

Local Institution - 0050

Aurora, Colorado, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Local Institution - 0055

South Miami, Florida, United States

Local Institution - 0081

New York, New York, United States

Local Institution - 0079

New York, New York, United States

Local Institution - 0066

Portland, Oregon, United States

Local Institution - 0071

Philadelphia, Pennsylvania, United States

Local Institution - 0051

DeSoto, Texas, United States

Local Institution - 0048

Merksem, Flanders, Belgium

Local Institution - 0049

Leuven, Belgium

Local Institution - 0083

Aparecida de Goiânia, Goiás, Brazil

Local Institution - 0033

Porto Alegre, Rio Grande do Sul, Brazil

Local Institution - 0082

Valinhos, São Paulo, Brazil

Local Institution - 0006

Beijing, Beijing Municipality, China

Local Institution - 0080

Guangzhou, Guangdong, China

Local Institution - 0010

Zhengzhou, Henan, China

Local Institution - 0007

Nanchang, Jiangxi, China

Local Institution - 0020

Shanghai, Shanghai Municipality, China

Local Institution - 0001

Shanghai, Shanghai Municipality, China

Local Institution - 0040

München, Bavaria, Germany

Charité Research Organisation

Berlin, Germany

Local Institution - 0021

Cologne, Germany

Local Institution - 0028

Herne, Germany

St. Josef-Stift Sendenhorst

Sendenhorst, Germany

Local Institution - 0019

Rozzano, Milano, Italy

Local Institution - 0017

Roma, Italy

Local Institution - 0053

México, Mexico

Local Institution - 0023

Józefów, Masovian Voivodeship, Poland

Local Institution - 0039

A Coruña, A Coruña [La Coruña], Spain

Local Institution - 0058

Córdoba, Córdoba, Spain

Local Institution - 0037

Bern, Switzerland

Local Institution - 0027

Geneva, Switzerland

Local Institution - 0060

Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine

Local Institution - 0064

Kyiv, Kyiv Oblast, Ukraine

Local Institution - 0063

Poltava, Poltava Oblast, Ukraine

Local Institution - 0061

Ternopil, Ukraine

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07412704

Related Trials

Clinical Outcomes of Primary Cementless Total Hip Arthroplasty Using the Collarless Actis Stem

NCT07828080

A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

NCT0624612359 locations

R-2487 in Patients With Rheumatoid Arthritis

NCT059615926 locations

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

NCT0717639062 locations

Fucoidan in the Treatment of Active Rheumatoid Arthritis

NCT070458961 location